Soeroso Noni Novisari, Tanjung Muhammad Faiz, Afiani Dina, Pradana Andika, Tarigan Setia Putra, Wahyuni Arlinda Sari
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Sumatera Utara, University of Sumatera Utara Hospital, Jl. Dr. Mansyur No.66 Medan 20154, Sumatera Utara, Indonesia.
Department of Public Health, Faculty of Medicine, University of Sumatera Utara, Jl. Dr. Mansyur No.66 Medan 20154, Sumatera Utara, Indonesia.
Open Access Maced J Med Sci. 2018 Nov 24;6(11):2123-2127. doi: 10.3889/oamjms.2018.421. eCollection 2018 Nov 25.
Serum Procalcitonin (PCT) is a biomarker that is frequently used to diagnose an infection. In some cases of thoracic malignancy, procalcitonin level appears to increase. However, the role of procalcitonin to diagnose malignancy is not certain yet, and the causes have not been known.
This study aimed to investigate procalcitonin levels in non-small cell lung cancer patients.
This was an observational study with a cross-sectional design. All lung cancer patients did not diagnose based on cytology/histopathology results with no evidence nor were signs and symptoms of infection recruited through consecutive sampling. The subtypes of lung cancer include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, staged III and IV. The procalcitonin levels were analysed from blood using immunofluorescent assay. Data were then analysed with the Chi-Square test by Epi Info™ 7 programs in which p-value < 0.05 was considered statistically significant.
A total of 68 lung cancer patients fulfilled the criteria of this study, 55 men (80.9%) and 13 women (19.1%). The highest percentage of cytology/histopathology type found was adenocarcinoma (80.9%), and 60.3% of those were diagnosed in stage IV. An increased procalcitonin level (greater than 0.01 ng/mL) occurred in 80.9% of Non-Small Cell Lung Cancer (NSCLC) patients. It appears that the higher the stage of lung cancer, the lower procalcitonin levels would be, although it was not statistically significant. There was no association between lung cancer subtype with procalcitonin levels.
An increased level of procalcitonin may be an indication not only for infection but also for Non-Small Cell Lung Cancer.
血清降钙素原（PCT）是一种常用于诊断感染的生物标志物。在一些胸段恶性肿瘤病例中，降钙素原水平似乎会升高。然而，降钙素原在诊断恶性肿瘤中的作用尚不明确，其原因也未知。
本研究旨在调查非小细胞肺癌患者的降钙素原水平。
这是一项采用横断面设计的观察性研究。所有肺癌患者均未根据细胞学/组织病理学结果诊断，且无感染证据及体征和症状，通过连续抽样纳入。肺癌亚型包括腺癌、鳞状细胞癌和大细胞癌，分期为III期和IV期。使用免疫荧光分析法从血液中分析降钙素原水平。然后通过Epi Info™ 7程序进行卡方检验分析数据，其中p值<0.05被认为具有统计学意义。
共有68例肺癌患者符合本研究标准，其中男性55例（80.9%），女性13例（19.1%）。发现的细胞学/组织病理学类型中比例最高的是腺癌（80.9%），其中60.3%在IV期被诊断。80.9%的非小细胞肺癌（NSCLC）患者降钙素原水平升高（大于0.01 ng/mL）。似乎肺癌分期越高，降钙素原水平越低，尽管无统计学意义。肺癌亚型与降钙素原水平之间无关联。
降钙素原水平升高可能不仅提示感染，还提示非小细胞肺癌。
